Ipilimumab

{
  "id": "MLC-T-ONC-004505",
  "term": "Ipilimumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair. Ipilimumab is used alone or with other drugs to treat certain types of colorectal cancer, esophageal cancer, hepatocellular carcinoma (a type of liver cancer), malignant pleural mesothelioma, melanoma, non-small cell lung cancer, and renal cell carcinoma (a type of kidney cancer). It is also being studied in the treatment of other types of cancer. Ipilimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called MDX-010 and Yervoy.",
    "A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system."
  ],
  "abbreviation": "MDX-CTLA-4",
  "synonyms": [
    "MDX-010",
    "Yervoy",
    "anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody",
    "monoclonal antibody CTLA-4",
    "MOAB CTLA-4",
    "ipilimumab biosimilar CS1002"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ipilimumab/"
}